IP Library Granted Patent US 10,226,370
Granted Patent B2
US 10,226,370 · App. 15/235,377 · Granted Mar 12, 2019

Stents and catheters having improved stent deployment

Inventors: Lucas Tradd Schneider (Plymouth, MN); Bryan Matthew Ladd (Minneapolis, MN); Richard Kusleika (Eden Prairie, MN); Richard Kravik (Champlin, MN); Sandra Vreeman (Circle Pines, MN)
Assignee: Covidien LP
A61F2/966A61F2/844A61F2/95A61F2/958A61F2/962A61F2002/9505A61F2002/9665A61F2210/0004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,226,370
App. No.
15/235,377
Granted
Mar 12, 2019
Kind
B2
Abstract

An implant delivery system and method comprises an implant, for example, a stent, and a delivery catheter. The stent has a scaffold with a coating or a shell that retains the scaffold in a collapsed configuration. The coating or shell is made of a material that dissolves or biodegrades upon exposure to a dissolution or biodegradation media. The stent is used with an implant delivery system which has a catheter with a catheter, wherein the stent is mounted on the catheter shaft. The catheter shaft is configured to be withdrawn through the patient's vessel when the scaffold is in its expanded configuration. Advantageously, the implant is thereby prevented from changing length during implant delivery and implant deployment.

Claims (35)

1. An implant delivery system comprising:

a catheter shaft;

a stent mounted on the catheter shaft, the stent including a scaffold having a collapsed configuration and an expanded configuration;

a shell surrounding the scaffold, the shell being configured to retain the scaffold in the collapsed configuration, the shell comprising tubing into which the scaffold is inserted, the shell being formed of a material that dissolves upon exposure to a dissolution media, and the scaffold being expandable from the collapsed configuration to the expanded configuration through exposure of the shell to the dissolution media, wherein the shell comprises perforations configured to assist fracture of the shell upon expansion of the scaffold; and

a tubular sheath covering, and in contact with, the shell while the scaffold is in the collapsed configuration, the tubular sheath being movable to expose the shell and enable the scaffold to expand from the collapsed configuration to the expanded configuration after at least a portion of the shell dissolves upon exposure to the dissolution media.

2. The implant delivery system of claim 1 , wherein the shell comprises at least one of preplaced slits or slots configured to assist fracture of the shell upon expansion of the scaffold.

3. The implant delivery system of claim 2 , wherein the shell comprises the preplaced slits, and wherein at least one of the preplaced slits is a longitudinal slit.

4. The implant delivery system of claim 1 , wherein the shell forms a smooth exterior surface over the scaffold.

5. The implant delivery system of claim 1 , wherein the scaffold is self-expanding.

6. The implant delivery system of claim 5 , wherein the scaffold is configured to self-expand to the expanded configuration as the shell dissolves.

7. The implant delivery system of claim 1 , wherein the scaffold is balloon-expandable.

8. The implant delivery system of claim 7 , further comprising a balloon interposed between the scaffold and the catheter shaft, wherein the balloon is configured to expand the scaffold to the expanded configuration as the shell dissolves.

9. The implant delivery system of claim 1 , wherein the shell is configured to maintain the scaffold in the collapsed configuration, and wherein the scaffold has an unexpanded diameter and a fixed length in the collapsed configuration.

10. The implant delivery system of claim 1 , wherein the tubular sheath is axially slidable relative to the stent.

11. The implant delivery system of claim 1 , wherein the shell comprises one or more antirestenotic agents.

12. The implant delivery system of claim 1 , wherein the shell comprises an anti-inflammatory agent.

13. The implant delivery system of claim 1 , wherein the shell comprises an antiatheromatic agent.

14. The implant delivery system of claim 1 , wherein the shell comprises an antioxidative agent.

15. The implant delivery system of claim 1 , further comprising a sheath seal configured to prevent the dissolution media from contacting the shell until the tubular sheath is moved to expose the shell to the dissolution media.

16. An implant delivery system comprising:

a catheter shaft;

a stent mounted on the catheter shaft, the stent including a scaffold having a collapsed configuration and an expanded configuration;

a shell surrounding the scaffold, the shell being configured to retain the scaffold in the collapsed configuration, the shell comprising a film wrapped around the scaffold, the shell being formed of a material that dissolves upon exposure to a dissolution media, and the scaffold being expandable from the collapsed configuration to the expanded configuration through exposure of the shell to the dissolution media, wherein the shell comprises perforations configured to assist fracture of the shell upon expansion of the scaffold; and

a tubular sheath covering, and in contact with, the shell while the scaffold is in the collapsed configuration, the tubular sheath being movable to expose the shell and enable the scaffold to expand from the collapsed configuration to the expanded configuration after at least a portion of the shell dissolves upon exposure to the dissolution media.

17. The implant delivery system of claim 16 , wherein the shell comprises at least one of preplaced slits or slots configured to assist fracture of the shell upon expansion of the scaffold.

18. The implant delivery system of claim 16 , wherein the scaffold is self-expanding.

19. The implant delivery system of claim 16 , wherein the scaffold is balloon-expandable.

20. The implant delivery system of claim 16 , wherein the shell comprises at least one of: an antirestenotic agent, an anti-inflammatory agent, an antiatheromatic agent, or an antioxidative agent.

21. The implant delivery system of claim 16 , further comprising a sheath seal configured to prevent the dissolution media from contacting the shell until the tubular sheath is moved to expose the shell to the dissolution media.

22. An implant delivery system comprising:

a catheter shaft;

a stent mounted on the catheter shaft, the stent including a scaffold having a collapsed configuration and an expanded configuration;

a shell surrounding the scaffold, the shell being configured to retain the scaffold in the collapsed configuration, the shell comprising tubing into which the scaffold is inserted, the shell being formed of a material that dissolves upon exposure to a dissolution media, and the scaffold being expandable from the collapsed configuration to the expanded configuration through exposure of the shell to the dissolution media, wherein the shell comprises local thinning of a wall thickness that assists fracture of the shell upon expansion of the scaffold; and

a tubular sheath covering, and in contact with, the shell while the scaffold is in the collapsed configuration, the tubular sheath being movable to expose the shell and enable the scaffold to expand from the collapsed configuration to the expanded configuration after at least a portion of the shell dissolves upon exposure to the dissolution media.

23. The implant delivery system of claim 22 , further comprising a sheath seal configured to prevent the dissolution media from contacting the shell until the tubular sheath is moved to expose the shell to the dissolution media.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2019
From: SCHNEIDER, LUCAS TRADD; LADD, BRYAN MATTHEW; KUSLEIKA, RICH; KRAVIK, RICK; KALLIO, SANDRA
To: EV3 INC.
Reel/Frame 048061/0491 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2019
From: EV3 PERIPHERAL, INC.
To: TYCO HEALTHCARE GROUP LP
Reel/Frame 048061/0576 →
CHANGE OF NAME Recorded Jan 18, 2019
From: TYCO HEALTHCARE GROUP LP
To: COVIDIEN LP
Reel/Frame 048098/0231 →
Continuity (4)
Continuation 13937820 · Jul 9, 2013
Continuation 12556997 · Sep 10, 2009
Provisional Application 61095766 · Sep 10, 2008
Related Publication 20160361186A1 · Dec 15, 2016